A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity

•We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Muc...

Full description

Saved in:
Bibliographic Details
Published inOral oncology Vol. 136; p. 106190
Main Authors Pan, Yanling, Li, Yijie, Yuan, Feng, Lin, Zhiren, Chai, Huizi, Xiao, Mingzhe, Chen, Dongsheng
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2023
Subjects
Abdominal Cavity - pathology
Carcinoma, Mucoepidermoid - pathology
Humans
Immune Checkpoint Inhibitors
Parotid Gland - pathology
Parotid Neoplasms - pathology
Online AccessGet full text

Cover

More Information
Summary:•We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Mucoepidermoid carcinoma of the parotid gland, anti-PD-1 immunotherapy could be considered to further improve therapeutic qualities and prognosis.•Our case showed an encouraging efficacy of Capecitabine plus sintilimab combination therapy. This promising avenue deserves further study to apply this combination regimen to clinical practice.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2022.106190